Back to Research Home
MDXGMiMedx Group Inc
Health Care · Medical/Dental Instruments · Small
$3.91−0.51%
As of 23 Oct 2026Mkt cap $663M
Stage 13
WAIT
Fundamentals
52.5/75
Technical
3.3/15
Independent
55.8/90
GCAE viewelevated earnings event risk blocks an independent BUY decision
Price
- 1M
- −17.0%
- 3M
- −8.2%
- 6M
- +14.0%
- 1Y
- −41.8%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- 97.8xHist median 21.0x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 13.2x
- FCF yield
- 7.6%
Quality
- ROIC
- 41.4%
- Operating margin
- 15.3%
- FCF margin
- 17.4%
- Current ratio
- 4.3x
Growth
- Revenue growth
- +20.0%Latest FY YoY
- Revenue CAGR
- +14.7%
- EPS CAGR
- −7.0%
- FCF CAGR
- +71.6%
Capital
- Share-count trend
- +1.3%3Y annualised
- Net cash
- $144M-1.9x OCF
Annual trend
- CAGR 2021–2025
- +14.7%
- Latest · 2025
- $0B
- YoY
- +20.0%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
elevated earnings event risk blocks an independent BUY decision
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-10-28
More details & evidence
Production decision
- Stage 13
- WAIT
- Technical state
- approaching-support
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded